Evidence map›Paper›PMID 19067453›Full record

ArticleChembiochem : a European journal of chemical biology2009

Inactivation of the ketoreductase gilU gene of the gilvocarcin biosynthetic gene cluster yields new analogues with partly improved biological activity.

Tao Liu, Madan K Kharel, Lili Zhu, Samuel A Bright, Cynthia Mattingly, Val R Adams, Jürgen Rohr

Open access · greenAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Ravidomycin Analogs fromJournal of natural products · 2023
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. GilR, an unusual lactone-forming enzyme involved in gilvocarcin biosynthesis.Chembiochem : a European journal of chemical biology · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tao LiuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, 725 Rose Street, Lexington, KY 40536-0082, USA.
Madan K Kharel
Lili Zhu
Samuel A Bright
Cynthia Mattingly
Val R Adams
Jürgen Rohr
University of Kentucky · US

Funding

BIOSYNTHETIC KEY STEPS OF ANGUCYCLINE ANTITUMOR DRUGSR01CA102102 · NCI · UNIVERSITY OF KENTUCKY · PI ROHR, JURGEN T · 2005 to 2009
$1.3M
NCI NIH HHS CA 102102NCI NIH HHS R01 CA102102
6 · The paper itself

Abstract

Four new analogues of the gilvocarcin-type aryl-C-glycoside antitumor compounds, namely 4'-hydroxy gilvocarcin V (4'-OH-GV), 4'-hydroxy gilvocarcin M, 4'-hydroxy gilvocarcin E and 12-demethyl-defucogilvocarcin V, were produced through inactivation of the gilU gene. The 4'-OH-analogues showed improved activity against lung cancer cell lines as compared to their parent compounds without 4'-OH group (gilvocarcins V and E). The structures of the sugar-containing new mutant products indicate that the enzyme GilU acts as an unusual ketoreductase involved in the biosynthesis of the C-glycosidically linked deoxysugar moiety of the gilvocarcins. The structures of the new gilvocarcins indicate substrate flexibility of the post-polyketide synthase modifying enzymes, particularly the C-glycosyltransferase and the enzyme responsible for the sugar ring contraction. The results also shed light into biosynthetic sequence of events in the late steps of biosynthetic pathway of gilvocarcin V.

Indexed as

Gene SilencingAlcohol OxidoreductasesAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationCoumarinsEscherichia coliGene DeletionGlycosidesHumansMiceMultigene FamilyStreptomyces lividansAlcohol OxidoreductasesAntineoplastic AgentsCoumarinsgilvocarcin VGlycosides

Identifiers

PMID19067453
PMCPMC2680003
OpenAlexW2088842106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.